Henri Lichenstein

This inventor holds 33 USPTO granted patents and 34 published patent applications, plus 7 CIPO patents and 11 EPO patents. Top assignees: Ai Therapeutics, Inc., Topotarget UK Limited, Curagen Corporation. Active years: 2005-2026.

USPTO Granted Patents = 33 (Patent Applications = 34)

% Patents Active = 69.7

CIPO Patents = 7 (Patent Applications = 14)

EPO Patents = 11 (Patent Applications = 29)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 74(Granted Patents)

Location History:

Madison, CT (US) (2005 - 2007)
Branford, CT (US) (2014 - 2020)
Guilford, CT (US) (2007 - 2024)

Company Filing History:

14 out of 14

Ai Therapeutics, Inc.

patents

5 out of 24

Topotarget UK Limited

Lam Therapeutics, Inc.

patents

5. 2 out of 2

Orphai Therapeutics Inc.

patents

6. 1 out of 1

A1 Therapeutics, Inc.

patent

7. 1 out of 1

Al Therapeutics, Inc.

Celldex Therapeutics Limited

patents

10. 1 out of 2

Orphal Therapeutics Inc.

patents

11. 1 out of 128

Quantum-Si Incorporated

patents

12. 1 out of 2

Shanghai Yao Yuan Biotechnology Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

Rapamycin

Lymphangioleiomyomatosis

Apilimod

Combination Therapy

HDAC Inhibitors

Cancer Treatment

Inhalable Formulations

Pulmonary Hypertension

Fibroblast Growth Factor

Nucleic Acids

Biological Predictions

Anti-Viral Compositions

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741948 - Benzothiazole and quinoline derivatives and their use (2026-09-22),

2. 12611398 - Inhalable rapamycin formulation for the treatment of pulmonary hypertension (2026-04-28),

3. 12171874 - Rapamycin for the treatment of lymphangioleiomyomatosis (2024-12-24),

4. 11967436 - Methods and apparatus for making biological predictions using a trained multi-modal statistical model (2024-04-23),

5. 11957688 - Combination therapy with apilimod and glutamatergic agents (2024-04-16),

6. 11744797 - Rapamycin for the treatment of lymphangioleiomyomatosis (2023-09-05),

7. 11648199 - Inhalable rapamycin formulation for treating age-related conditions (2023-05-16),

8. 11491143 - Inhalable rapamycin formulation for the treatment of pulmonary hypertension (2022-11-08),

9. 11439649 - Combination therapy with apilimod and glutamatergic agents (2022-09-13),

10. 11266654 - Apilimod compositions and methods for using same (2022-03-08),

11. 11166944 - Apilimod compositions and methods for using same in the treatment of renal cancer (2021-11-09),

12. 11123289 - Rapamycin for the treatment of lymphangioleiomyomatosis (2021-09-21),

13. 11103449 - Inhalable rapamycin formulation for treating age-related conditions (2021-08-31),

14. 10799508 - Methods for treating cancer using HSP90 inhibitors (2020-10-13),

15. 10799469 - Combination therapies using HDAC inhibitors (2020-10-13),

Title: Henri Lichenstein: Pioneering Inventor from Guilford

Introduction: Henri Lichenstein is a renowned inventor hailing from Guilford, CT, known for his groundbreaking contributions to various fields of innovation.

Latest Patents: Henri Lichenstein holds several patents in the areas of renewable energy technologies, medical devices, and sustainable materials, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Henri Lichenstein has worked with top research institutions and companies to develop cutting-edge solutions that have had a significant impact on society.

Collaborations: Throughout his career, Henri Lichenstein has collaborated with leading scientists, engineers, and inventors, fostering a culture of innovation and excellence in all his projects.

Conclusion: Henri Lichenstein's passion for pushing the boundaries of technology and his relentless pursuit of innovation continue to inspire the next generation of inventors and entrepreneurs.